Patient Engagement for Medtech Companies is Hard: Here’s Some Advice on How to Do it Right

Interview with Neal Sofia

Engaging with patients in a genuine and transparent way is tough.  Really tough.  It’s challenging for all healthcare stakeholders – payers, providers, and industry.

From a medtech perspective, we often times get stuck in a certain mindset when trying to engage with patients. Whether it’s a continuous glucose monitor for diabetic patients or a new hip implant for orthopedic patients, we gravitate towards communicating the features and benefits of our particular product.  For example, this might sounds familiar – “Joe Patient, you should consider our knee implant because it has a greater arc than Competitor X.”

But is this really the right approach?  If our end-goal is for a patient to take action, is this the best way to engage with them?  To answer this question, I invited Neal Sofian to the program.  He’s currently the VP of Engagement & Innovation at Vivacity, a subsidiary of Premera Blue Cross.  Neal is recognized internationally for his work in population health management and behavioral change.

Interview Highlights with Neal Sofian

  • What does patient personalization really mean?  And why messaging around life and context is so important.
  • Why do so many life science companies fail to effectively personalize their messages to patients?
  • What technologies can actually support effective patient engagement?
  • Examples of companies that have been successful at patient personalization.
  • How to overcome some of the legal challenges associated with patient engagement.
  • The top 2 things that medtech or biotech companies should do right now to improve their patient engagement initiatives.
  • Neal’s favorite non-fiction business book, the business leaders he admires the most, and the one piece of advice he’d give to his 30-yr. old self.
Guest
Neal Sofian
VP at Vivacity

Neal Sofian is recognized internationally for over 35 years of innovation in population and corporate health management as well as organizational change.  He is responsible for commercializing the first telephonic coaching programs including Free & Clear and many of the early social networking platforms including the Cancer Society’s ‘Cancer Survivors Network’.  Neal is currently the VP of Engagement & Innovation at Vivacity, a subsidiary of Premera Blue Cross.  He develops new strategies to actively engage the 2 million members of Premera in their health and wellbeing.  He is also a clay artist and has done standup comedy.  Neal holds a master’s degree in public health from the University Of Missouri School Of Medicine.

Download a copy of the interview transcript right here.
Share:
Twitter
Facebook
LinkedIn
Email

Engaging with patients in a genuine and transparent way is tough.  Really tough.  It’s challenging for all healthcare stakeholders – payers, providers, and industry.

From a medtech perspective, we often times get stuck in a certain mindset when trying to engage with patients. Whether it’s a continuous glucose monitor for diabetic patients or a new hip implant for orthopedic patients, we gravitate towards communicating the features and benefits of our particular product.  For example, this might sounds familiar – “Joe Patient, you should consider our knee implant because it has a greater arc than Competitor X.”

But is this really the right approach?  If our end-goal is for a patient to take action, is this the best way to engage with them?  To answer this question, I invited Neal Sofian to the program.  He’s currently the VP of Engagement & Innovation at Vivacity, a subsidiary of Premera Blue Cross.  Neal is recognized internationally for his work in population health management and behavioral change.

Interview Highlights with Neal Sofian

  • What does patient personalization really mean?  And why messaging around life and context is so important.
  • Why do so many life science companies fail to effectively personalize their messages to patients?
  • What technologies can actually support effective patient engagement?
  • Examples of companies that have been successful at patient personalization.
  • How to overcome some of the legal challenges associated with patient engagement.
  • The top 2 things that medtech or biotech companies should do right now to improve their patient engagement initiatives.
  • Neal’s favorite non-fiction business book, the business leaders he admires the most, and the one piece of advice he’d give to his 30-yr. old self.
Guest
Neal Sofian
VP at Vivacity

Neal Sofian is recognized internationally for over 35 years of innovation in population and corporate health management as well as organizational change.  He is responsible for commercializing the first telephonic coaching programs including Free & Clear and many of the early social networking platforms including the Cancer Society’s ‘Cancer Survivors Network’.  Neal is currently the VP of Engagement & Innovation at Vivacity, a subsidiary of Premera Blue Cross.  He develops new strategies to actively engage the 2 million members of Premera in their health and wellbeing.  He is also a clay artist and has done standup comedy.  Neal holds a master’s degree in public health from the University Of Missouri School Of Medicine.

Download a copy of the interview transcript right here.
Share:
Twitter
Facebook
LinkedIn
Email

You May Like These Articles

Premium

Connecting the Dots Between Medtech and AI

Interview with Sonio CEO Cecile Brosset

In this interview, we talk to Cecile Brosset Dubois about her transition from renowned consulting firms like Bain & Company to leading her own medtech startup, Sonio, which focuses on enhancing obstetric ultrasound with AI. We touch on her strategic approach to product development, the importance of an in-house regulatory team, her drive for meaningful work, and effective tactics for fundraising.

Premium

Think Big, Start Small, and Prioritize Ruthlessly

Interview with InterShunt CEO Harlee Sorkin

Harlee Sorkin’s company, InterShunt Technologies, is leading the development of a groundbreaking minimally invasive catheter designed to treat heart failure. The technique they use focuses on creating a shunt within the heart. By improving blood flow and lessening the heart's workload, it holds promise of easing heart failure symptoms, potentially setting a new standard in patient care. In this interview, Harlee delves into the nuances of leading an early-stage medtech company and covers essential topics such as development prioritization and capital fundraising. He also shares what it’s like to navigate clinical and regulatory challenges as a first-time medtech entrepreneur and how to effectively engage with stakeholders across the healthcare ecosystem.

Premium

Medsider Mentors

Volume VI

In Medsider Mentors Volume VI, we’ve distilled key insights from founders and CEOs of some of the hottest medical device and health technology startups including LimFlow, Field Medical, Sinaptica, Spark Biomedical, InterShunt and many more.

View More Interviews
See the Playbooks

Join Medsider as a Free Subscriber

Subscribe to Medsider and get access to exclusive benefits for free. No spam, 100% privacy, and your email won’t be shared.